

Global Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs and Companies Pipeline Review H2 2016

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Treatment Pipeline Review H2 2016

PUNE, INDIA, September 12, 2016

/EINPresswire.com/ -- [Hodgkin Lymphoma \(B-Cell Hodgkin Lymphoma\)](#) - Pipeline Review, H2 2016 Summary

'Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016', provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.



Complete report details @ <https://www.wiseguyreports.com/reports/636761-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/636761-hodgkin->

[lymphoma-b-cell-hodgkin-lymphoma-pipeline-review-h2-2016](https://www.wiseguyreports.com/enquiry/636761-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-pipeline-review-h2-2016)

Scope

- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
- The report reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects
- The report assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/636761-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-pipeline-review-h2-2016>

Key points in table of content

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Overview 9

Therapeutics Development 10

Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview 10

Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis 11

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics under Development by Companies

12

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics under Investigation by Universities/Institutes 15

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Products under Development by Companies 19

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Products under Investigation by Universities/Institutes 23

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development 24

4SC AG 24

AbbVie Inc 25

Acetylon Pharmaceuticals, Inc. 26

Actinium Pharmaceuticals, Inc. 27

ADC Therapeutics Sarl 28

Affimed GmbH 29

Amgen Inc. 30

Arno Therapeutics, Inc. 31

Bellicum Pharmaceuticals, Inc. 32

Bristol-Myers Squibb Company 33

Celgene Corporation 34

Cell Medica Limited 35

Cellular Biomedicine Group, Inc. 36

Constellation Pharmaceuticals, Inc. 37

Curis, Inc. 38

Faron Pharmaceuticals Oy 39

Gamida Cell Ltd. 40

Incyte Corporation 41

Merck & Co., Inc. 42

Merck KGaA 43

Mesoblast Limited 44

Millennium Pharmaceuticals Inc 45

Mirati Therapeutics Inc. 46

Molecular Templates Inc. 47

NantKwest, Inc. 48

Ono Pharmaceutical Co., Ltd. 49

Pfizer Inc. 50

Philogen S.p.A. 51

Polyphor Ltd. 52

Rich Pharmaceuticals, Inc. 53

Seattle Genetics, Inc. 54

Selvita S.A. 55

Sigma-Tau S.p.A. 56

Spectrum Pharmaceuticals, Inc. 57

Stemline Therapeutics, Inc. 58

Taiwan Liposome Company, Ltd. 59

Takeda Pharmaceutical Company Limited 60

TG Therapeutics, Inc. 61

Theravectys SA 62

TRACON Pharmaceuticals, Inc. 63

Trillium Therapeutics Inc. 64
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Target 67
Assessment by Mechanism of Action 72
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
(INCB-039110 + INCB-040093) - Drug Profile 82
ADCT-301 - Drug Profile 83
AFM-13 - Drug Profile 84
Alocrest - Drug Profile 88
AR-42 - Drug Profile 90
avelumab - Drug Profile 92
azacitidine - Drug Profile 97

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=636761

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.